Systemic Immune-Inflammation Index a Strong Predictor of Outcomes in Patients with DLBCL
A study found that the systemic immune-inflammation index (SII) is [...]
| Categories: lymphoma
A study found that the systemic immune-inflammation index (SII) is a robust prognostic tool for diffuse large B cell lymphoma (DLBCL). To conduct this study, […]
A study found that the systemic immune-inflammation index (SII) is [...]
A study found that increased 18F-FDG PET/CT heterogeneity may predict [...]
Total lesion glycolysis (TLG) and National Comprehensive Cancer Network International [...]
A high expression of methyltransferase EZH2 shortens survival in patients [...]
Diffuse large B-cell lymphoma (DLBCL) patients infused with an autograft [...]
A study identified several potential miRNAs as biomarkers for diffuse [...]
A study published in the Journal of Clinical Oncology characterized [...]
A study found that the expression of miR-155 and the [...]
Some patients with primary refractory diffuse large B-cell lymphoma (DLBCL) [...]
Researchers of a study do not recommend maintenance therapy in [...]
Short diagnosis-to-treatment (DTI) and circulating tumor DNA (ctDNA) levels in [...]
Interim 3′-deoxy-3′-[18F]fluorothymidine (iFLT) PET/CT was superior to interim 18F-fluorodeoxyglucose (iFDG) PET/CT [...]
A study assessed different treatment modalities for patients with sinonasal [...]
A study found that surgery may be a beneficial treatment [...]
The risk of second malignant neoplasms (SMNs) in patients with [...]